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Multiple myeloma can be accurately
diagnosed in acute kidney injury patients
using a rapid serum free light chain test
Jennifer L. J. Heaney1†, John P. Campbell1,2†, Punit Yadav1,3, Ann E. Griffin1, Meena Shemar4,
Jennifer H. Pinney1,3 and Mark T. Drayson1*
Abstract
Background: Acute kidney injury (AKI) is common in patients with multiple myeloma (MM). Whether serum free
light chain (sFLC) measurements can distinguish between myeloma and other causes of AKI requires confirmation
to guide early treatment. A rapid and portable sFLC test (Seralite®) is newly available and could reduce delays in
obtaining sFLC results and accelerate diagnosis in patients with unexplained AKI. This study evaluated the accuracy
of Seralite® to identify MM as the cause of AKI.
Method: sFLCs were retrospectively analysed in patients with AKI stage 3 as per KDIGO criteria (i.e. serum
creatinine ≥354 μmol/L or those on dialysis treatment) (n = 99); 45/99 patients had a confirmed MM diagnosis.
Results: The Seralite® κ:λ FLC ratio accurately diagnosed all MM patients in the presence of AKI: a range of 0.14–2.02
returned 100% sensitivity and specificity for identifying all non-myeloma related AKI patients. The sFLC difference
(dFLC) also demonstrated high sensitivity (91%) and specificity (100%): an optimal cut-off of 399 mg/L distinguished
between myeloma and non-myeloma AKI patients. We propose a pathway of patient screening and stratification in
unexplained AKI for use of Seralite® in clinical practice, with a κ:λ ratio range of 0.14–2.02 and dFLC 400 mg/L as
decision points.
Conclusions: Seralite® accurately differentiates between AKI due to MM and AKI due to other causes in patients
considered at risk of myeloma. This rapid test can sensitively screen for MM in patients with AKI and help inform early
treatment intervention.
Keywords: Myeloma, Acute kidney injury, Renal impairment, Serum free light chain, Patient screening
Background
Acute kidney injury (AKI) is a common complication of
multiple myeloma and has been recommended to be
treated as a medical emergency [1]. Renal impairment
contributed to nearly a third of deaths that occurred
within 60 days of diagnosis in myeloma patients enrolled
in UK clinical trials between 1980 and 2002 [2]. Al-
though the survival of myeloma patients presenting with
severe renal impairment has significantly improved with
modern anti-myeloma therapy the risk of early death
remains high [3]. Cast nephropathy (also known as mye-
loma kidney) is the most common cause of severe renal
impairment in patients with myeloma, which occurs due
to the aggregation of filtered FLC and Tamm-Horsfall pro-
tein in the distal tubule [1]. Nephrotoxic FLCs can cause
renal impairment as an early feature of myeloma, prior to
other disease-associated organ or tissue damage [4]. AKI
secondary to cast nephropathy is only likely when the
serum FLC (sFLC) level is ≥500 mg/L [5]. Myeloma-
related complications such as hypercalcaemia and dehy-
dration can also cause or exacerbate renal injury [4].
In patients presenting with an AKI where the underlying
pathology is unknown, myeloma should be investigated as
a potential cause; this requires a robust screening method
to be in place [6, 7]. The presence of elevated FLCs and a
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perturbed sFLC κ:λ ratio is a key marker for detecting
plasma cell malignancies and has been shown to be an im-
portant indicator of myeloma in the presence of AKI. The
first commercially available sFLC assay (Freelite®, The
Binding Site, UK) was utilised to determine a κ:λ ratio ref-
erence range in patients with renal impairment, without
monoclonal gammopathy (renal reference range 0.37–3.1)
[8]. This κ:λ ratio range on Freelite® has been demon-
strated to provide 100% sensitivity and 99% specificity in
identifying multiple myeloma in 41 patients who pre-
sented with AKI but has yet to be confirmed in a separate
set of myeloma patients [9].
Renal impairment in myeloma has been shown to be
reversible in approximately 50% of patients presenting
with moderate (plasma creatinine 130–200 μmol/L) to
severe (plasma creatinine >200 μmol/L) renal impair-
ment, and recovery of renal function can improve pa-
tient survival [10]. Prompt identification and reduction
of monoclonal FLCs by anti-myeloma therapy is vital for
renal recovery and the prevention of irreversible damage
[11–13]. Similarly, in cases where myeloma is not the
cause of AKI, it is important to rule this out quickly so
that patients can be referred for a kidney biopsy and fur-
ther clinical investigation. Speed is therefore critical in
diagnosing the underlying pathology in AKI. sFLCs as-
says run on nephelometric or turbidimetric analysers,
such as Freelite® and N Latex (Siemens, Germany), are not
usually performed in daily batches and often necessitate
sending patient samples to specialist laboratories at exter-
nal sites. This can result in slow turn-around times and
delays in receiving patient results. Seralite® (Abingdon
Health Ltd., UK) is a lateral-flow test that rapidly quanti-
tates serum κ and λ FLC levels simultaneously in 10 min,
which can be easily used as an urgent assay for small
numbers of samples in routine hospital laboratories. Sera-
lite® and associated FLC assays using the same anti-FLC
reagents have already been shown to perform well in diag-
nosing and monitoring multiple myeloma in the absence
of severe renal impairment [14–17].
The aims of this study were to assess the utility of Ser-
alite® as a screening tool to distinguish between myeloma
and non-myeloma related AKI, and provide a reference
range for diagnostic purposes in patients presenting with
AKI stage 3 where renal impairment was classified as




The present study was a retrospective investigation of
patients with AKI stage 3 as per the KDIGO classifica-
tion (n = 99) with stored serum samples available at dis-
ease presentation. Patients were included from two
separate investigations. Forty five patients were enrolled
in the MyEloma Renal Impairment Trial (MERIT:
ISRCTN37161699) for patients with newly diagnosed
myeloma associated with acute renal failure (creatinine
>500 μmol/L, urine output <400 mL/d or requiring dia-
lysis), attributable to myeloma. In the present study,
stored serum was analysed from MERIT patients at trial
entry. The other patients (n = 54) presented with new
dialysis-dependent renal failure to the renal unit at the
University Hospital Birmingham (UHB). These patients
were identified from retrospective analyses of 1090 pa-
tients who were admitted to UHB with AKI over a 3 year
period. Patients were selected on the basis of stored
serum at the time of admission from undergoing initial
laboratory screening for a plasma cell disorder. Patients
had AKI with an aetiology other than myeloma con-
firmed through kidney biopsies (n = 19) and other clin-
ical investigations (n = 35) (non-myeloma related AKI).
Healthy individuals (n = 91) were also included with
serum samples obtained from healthy random donors
from the NHS Blood and Transplant service (NHSBT,
Birmingham, UK). These donors were anonymous with
unknown age and medical history.
Serum sample analyses
All serum samples underwent analysis for FLCs using
Seralite® - a portable lateral-flow test that utilises anti-
FLC monoclonal antibodies (Abingdon Health Ltd., Ox-
ford, UK) enabling simultaneous quantification of κ and
λ FLC levels (described in full elsewhere) [14]. Healthy
donor patient samples were also analysed for creatinine
(Roche Hitachi Cobas C501).
Data analyses
The following sFLC parameters were assessed: absolute
κ and λ FLC levels, the κ:λ ratio (κ FLC ÷ λ FLC), FLC
sum (κ FLC + λ FLC) and the FLC difference (dFLC; cal-
culated as the involved minus the uninvolved LC in
myeloma patients and the higher FLC minus the lower
FLC in patients without myeloma and healthy donors).
Kruskal-Wallis tests were used to examine differences in
FLC parameters measured by Seralite® between groups:
AKI patients with myeloma and κ FLC diagnosis, AKI
patients with myeloma and λ FLC diagnosis, AKI pa-
tients without myeloma and healthy donors. Significant
differences were analysed with Dunn’s test post-hoc
comparisons. Receiver operating characteristic (ROC)
curves were used to assess if sFLC parameters, κ:λ ratio,
FLC sum and dFLC, could be used to differentiate be-
tween patients with AKI and myeloma and patients with
AKI without myeloma. Accuracy was classified using
area under the curve (AUC). Best cut-offs were identi-
fied using the points on curve closest to the (0, 1); dis-
tance was calculated for each observed cut-off point
from the curve (distance = √[(1 – sensitivity)2 + (1 –
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specificity)2] and the point where the distance was mini-
mum was selected. All analyses were conducted using
IBM SPSS statistics version 21.
Results
Participants
Myeloma AKI stage 3 patients were aged between 39 and
98 years with a median age of 69 years. Non-myeloma AKI
stage 3 patients were aged between 21 and 89 years with a
median age of 68 years. There was no significant difference
in the age of patient groups nor was there a difference in
the proportion of patients aged ≥65 years old: 67% of mye-
loma patients and 56% of non-myeloma patients were aged
≥65 years. The distribution of sex between the groups did
not significantly differ; 56% of myeloma AKI patients and
65% of non-myeloma AKI patients were male. Healthy do-
nors were also included; all with creatinine levels
≤114 μmol/L (mean 81 ± 15 μmol/L).
Seralite® to differentiate between AKI with myeloma, AKI
without myeloma and healthy donors
Table 1 details full descriptive statistics for all FLC pa-
rameters by group. Figure 1 illustrates κ FLC and λ FLC
levels in the different cohorts. Significant differences be-
tween groups were observed for κ FLC (X2 = 132.2,
p < .001). Myeloma patients (both κ and λ isotype
groups) differed to non-myeloma related AKI patients;
myeloma κ FLC patients had significantly higher κ FLC
levels, and myeloma λ FLC patients had significantly
lower κ FLCs, compared with AKI patients without mye-
loma. Both myeloma κ and non-myeloma related AKI
patients had κ FLC levels above healthy donor levels.
Significant differences between groups were also ob-
served for λ FLCs (X2 = 146.4, p < .001). Similarly, both
myeloma groups differed to non-myeloma related AKI
patients, where myeloma λ patients had higher and κ pa-
tients had lower λ FLCs levels than non-myeloma AKI
patients. All patient groups had higher λ FLC levels
compared with healthy donors. Despite these differences
between myeloma AKI patients and AKI patients with-
out myeloma, there was an overlap between the distribu-
tion of κ and λ FLC levels between groups.
The κ:λ ratio revealed complete separation between
patient groups (Fig. 2). All myeloma patients exhibited a
perturbed ratio outside the healthy diagnostic range
(0.5–2.5). There was no overlap in κ:λ ratios between
myeloma κ AKI patients (ratio ≥ 2.8) and myeloma λ pa-
tients (ratio ≤ 0.009) and non-myeloma AKI patients (ra-
tio 0.2–1.3). The difference between groups was
statistically significant (X2 = 156.1, p < .001); the non-
myeloma AKI group had a lower/higher ratio compared
with myeloma κ and λ patients with AKI, respectively.
Myeloma patients had significantly different ratios com-
pared with healthy donors. Non-myeloma AKI patients
had a lower ratio than healthy donors as a result of
higher λ FLC levels relative to κ FLC levels. In these pa-
tients λ FLC levels were higher than κ levels in 52/54
(96%) patients (in healthy donors λ FLCs were higher
than κ in 34/91 (37%) of cases); 48/54 (89%) were below
the ratio healthy diagnostic range (0.5–2.5), with the 6
other patients within the range.
The groups had significantly different FLC sums
(X2 = 157.5, p < .001) and dFLC values (X2 = 153.1,
p < .001) (Fig. 3). Both κ and λ myeloma AKI patients
had higher FLC sums and dFLC values compared with
non-myeloma AKI patients. However, unlike the κ:λ ra-
tio, there was an overlap in the distribution of FLC sums
and dFLC values and complete differentiation between
groups was not seen with these FLC parameters. All pa-
tients had higher FLC sums and dFLC values compared
with healthy donors.
Seralite® sFLC cut-offs to differentiate between AKI pa-
tients with myeloma and AKI without myeloma
ROC analyses results for sFLC parameters to identify
myeloma in AKI patients are presented in Table 2. The
Table 1 Free light chain (FLC) parameters from serum samples analysed using Seralite®


















































Patients included multiple myeloma patients with a monoclonal κ or λ FLC and acute kidney injury (AKI), patients with non-myeloma related AKI and
healthy donors
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κ:λ ratio gave an AUC of 1.0 indicating this parameter
was able to classify myeloma from non-myeloma AKI
patients with perfect accuracy. Myeloma κ patients al-
ways had higher ratios and myeloma λ patients always
lower ratios compared to non-myeloma AKI patients
resulting in no false positives/false negatives. Accord-
ingly, this sFLC parameter provided 100% sensitivity and
100% specificity for differentiating between myeloma
and non-myeloma related AKI. The optimal cut-offs
were 0.14 to identify λ patients and 2.02 to distinguish κ
patients. These values can be used to inform an adapted
renal reference range for use with this test in patients
presenting with AKI stage 3. The FLC sum and dFLC
also provided a high level of accuracy for identifying
Fig. 1 Serum κ FLC (a) and λ FLC (b) levels analysed using Seralite®. Data is shown for patients with multiple myeloma (with either a monoclonal
κ or λ FLC) and acute kidney injury (AKI), patients with AKI without myeloma (non-myeloma related AKI) and healthy donors. Boxes show the
interquartile range, with the line indicating the median, and the whiskers show the minimum and maximum. * indicates a significant difference
to the non-myeloma related AKI group; † indicates a significant difference to healthy donors; p < .01 for all comparisons
Fig. 2 Serum κ:λ FLC ratio analysed using Seralite®. Data is shown for patients with multiple myeloma (with either a monoclonal κ or λ FLC) and
acute kidney injury (AKI), patients with AKI without myeloma (non-myeloma related AKI) and healthy donors. Boxes show the interquartile range,
with the line indicating the median, and the whiskers show the minimum and maximum. * indicates a significant difference to the non-myeloma
related AKI group; † indicates a significant difference to healthy donors; p < .05 for all comparisons
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myeloma from non-myeloma AKI. AUCs of .97 and .99
were observed for the FLC sum and dFLC, respectively.
The best-cut-offs were 528 mg/L for FLC sum (84% sen-
sitivity, 94% specificity) and 399 mg/L for dFLC (91%
sensitivity, 100% specificity).
Discussion
This study assessed whether a new portable sFLC test
could serve as a rapid screening tool for myeloma in pa-
tients presenting with AKI. Seralite® was able to provide
differential diagnosis between myeloma and non-
myeloma related AKI. The ROC analyses showed with a
100% certainty that myeloma κ AKI patients would have
a higher κ:λ ratio, and myeloma λ AKI patients would
have a lower κ:λ ratio, than non-myeloma AKI patients.
The κ:λ ratio discriminated between patients with per-
fect accuracy with no false positives or false negatives
with optimal cut-offs of 0.14 and 2.02; this represents an
appropriate reference range to apply when using Sera-
lite® in patients with severe renal impairment. The FLC
sum and dFLC also provided a high level of accuracy for
identifying myeloma in these patients, with optimal cut-
offs of 528 mg/L for FLC sum and 399 mg/L for dFLC.
The dFLC offered the best combination of sensitivity
(91%) and specificity (100%). Although absolute levels of
κ and λ FLCs were significantly different between groups
there was overlap in the distribution between myeloma
and non-myeloma patient results. This is consistent with
previous findings where only the κ:λ FLC ratio showed
very good sensitivity for myeloma cast nephropathy [19].
Importantly, the portable device offered the same level
of diagnostic performance previously reported for con-
ventional laboratory-based testing. The published renal
reference for the κ:λ ratio using Freelite® (0.37–3.1) is
Fig. 3 Serum FLC sum (a) and FLC difference (dFLC, b) analysed using Seralite®. Data is shown for patients with multiple myeloma (with either a
monoclonal κ or λ FLC) and acute kidney injury (AKI), patients with AKI without myeloma (non-myeloma related AKI) and healthy donors. Boxes
show the interquartile range, with the line indicating the median, and the whiskers show the minimum and maximum. * indicates a significant
difference to the non-myeloma related AKI group; † indicates a significant difference to healthy donors; p < .01 for all comparisons. FLC sum = κ
FLC + λ FLC; dFLC difference = involved minus the uninvolved LC in myeloma patients/maximum FLC minus the minimum FLC in patients with-
out myeloma and healthy donors
Table 2 Serum FLC parameters to differentiate patients with and without myeloma in patients presenting with AKI
AUC Best cut-off Sensitivity Specificity
Ratio: myeloma κ 1.0
(95% CI 1–1, p < .001)
2.02 100% 100%
Ratio: myeloma λ 1.0
(95% CI 1–1, p < .001)
0.14 100% 100%
FLC sum 0.97
(95% CI .94–.1.0, p < .001)
528 mg/L 89% 94%
dFLC 0.99
(95% CI .97–1.0, p < .001)
399 mg/L 91% 100%
Data is shown ROC analyses for the κ:λ ratio, FLC sum and FLC difference (dFLC) measured using Seralite®. Area under curve (AUC, with 95% confidence intervals
[CI]) was calculated and the best cut-off point identified with associated sensitivity and specificity are reported for each FLC parameter
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associated with 100% sensitivity and 99% specificity for
detecting nephrotoxic monoclonal FLCs in 41 myeloma
patients with AKI [9]. The other commercially available
method of sFLC quantitation, N Latex, currently has no
published validation of sFLC measurement in patients
with myeloma and AKI. However, evaluation has been
carried out with N Latex in patients with renal impair-
ment (without myeloma) where, unlike Seralite® and
Freelite®, an adapted κ:λ ratio renal reference range was
found not to be required [20]. Good clinical concord-
ance has been shown between the different sFLC
methods previously [14, 15, 17]. However, it is essential
to remember that assays cannot be used interchangeably
as they quantitate sFLC levels in different ways, particu-
larly monoclonal FLCs [14, 15, 20, 21]. Users need to en-
sure consecutive samples from individual patients are
compared using the same assay, taking into account the
specific healthy and renal reference limits provided by
the different tests.
It is estimated that 50% of patients with myeloma-
related AKI initially present to nephrology services [22].
sFLC laboratory assays have made important progress in
reducing delays associated with other methods of mono-
clonal FLC testing (serum and urine protein electrophor-
esis, immunofixation electrophoresis) [9]. However, FLC
nephelometric and turbidimetric assays are not available
in all hospitals, often necessitating sample dispatch to
specialised laboratories. When using automated analy-
sers, samples are routinely run in batches and thus test-
ing may not be carried out every day. This can lead to
sample turn-around times of days to weeks and cause
delays that may jeopardise the chance of renal recovery.
Seralite® accelerates the processing of urgent samples
and it could be used to generate results in 10 min by
any hospital that operates a 24 h laboratory service.
Early diagnosis and treatment intervention in myeloma
is central to disease-free survival [2, 23] but is particu-
larly important in the context of myeloma and AKI.
Swift treatment intervention to reduce monoclonal FLCs
and halt injury is essential: a 60% reduction in FLCs by
day 21 has been associated with recovery of renal func-
tion for 80% of the population [11]. Seralite® identifica-
tion of abnormal sFLC levels could enable quicker
treatment initiation and in turn potentially improve
renal recovery rates in myeloma AKI patients. Further,
by quickly identifying a high probability of cast nephrop-
athy patients may be spared the risk of a renal biopsy.
Screening pathways have been proposed for myeloma
in AKI based upon Freelite® sFLC levels [5, 13]. In these
algorithms, when patients have a κ:λ ratio outside the
renal reference range, a sFLC level ≥ 500 mg/L on Free-
lite® indicates a high probability of myeloma cast ne-
phropathy. Consequently, a renal biopsy may not be
necessary [24]. High-dose dexamethasone can induce up
to a 100-fold reduction of sFLCs within 14 days: imme-
diate administration is crucial in myeloma cast neur-
opathy and is often started prior to deciding a full
programme of induction therapy [12, 13]. Early treat-
ment with dexamethasone could be given to patients
who are identified as having a high chance of cast ne-
phropathy via Seralite®. In Fig. 4 we make suggestions
for the use of Seralite® in clinical practice for patient
screening and stratification in patients with unexplained
AKI who are thought to be at risk of myeloma. Using
this pathway, the κ:λ ratio could be used to identify
monoclonal FLC and the dFLC to aid subsequent deci-
sions for clinical management. If an abnormal κ:λ ratio
(< 0.14 or >2.02) is identified, a dFLC threshold of
≥400 mg/L can be used to confirm a high likelihood of
cast neuropathy. We recommend patients with an ab-
normal ratio and a dFLC level of ≥400 mg/L should be
considered for immediate treatment with high-dose
dexamethasone (guided by haematology and nephrology
teams), while concurrently expediting additional labora-
tory and clinical investigations to confirm myeloma diag-
nosis, and a renal biopsy is not indicated. Due to the
high specificity observed in this study, it is extremely un-
likely that using these criteria would result in an AKI pa-
tient without myeloma being administered high-dose
dexamethasone. As a result of the high sensitivity of this
test, it can be expected that missing myeloma patients
using sFLC screening would occur only in rare circum-
stances. In the case of a dFLC <400 mg/L on Seralite®,
caution should be taken, awaiting haematological results
before considering initiating dexamethasone therapy; if
haematological investigations remain inconclusive a bi-
opsy may be required to establish the cause of AKI. For
all patients where an abnormal ratio is identified, irre-
spective of the observed sFLC level, a comprehensive
haematological work-up is required urgently. Full anti-
myeloma therapy should certainly not be considered
until the diagnostic criteria for multiple myeloma, in-
cluding a bone marrow biopsy, have been fulfilled.
Myeloma usually only accounts for a few percent of
new AKI stage 3 cases and so it remains necessary to
test the sensitivity and specificity of Seralite® in a popula-
tion where the proportion of myeloma cases is close to
that, rather than nearly half as in this study. A further
limitation of the present investigation is the retrospect-
ive study design. Although serum samples were collected
at the time of myeloma presentation/screening for mye-
loma, sFLC testing by Seralite® was carried out later.
Findings should be confirmed in a prospective study in
clinical practice with ‘real time’ Seralite® testing when
patients present with AKI. Prospective studies are also
required to refine criteria for screening individual pa-
tients and assess the health economics of screening.
While sFLC screening across all patients with AKI where
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the cause is unknown may be the ideal to ensure poten-
tial myeloma patients are not missed, this approach is
not feasible or indeed necessary based upon the ex-
pected prevalence of myeloma: here, out of 1090 pa-
tients admitted to the renal unit at UHB, 4% had
myeloma. Consequently, patient subgroups most appro-
priate for screening based on risk of myeloma need to
be identified. Myeloma most commonly occurs in indi-
viduals aged over 60 (80% of myeloma patients in the
present study) and this would be a simple criterion to
initially stratify patient screening. Age and other clinical
factors should be examined to further develop screening
strategies for myeloma in AKI.
In a previous investigation of myeloma patients pre-
senting with AKI at diagnosis who underwent a renal bi-
opsy, the principal pathology in nearly 90% of patients
was cast nephropathy as a consequence of excess and
nephrotoxic monoclonal FLCs [25]. Therefore, myeloma
patients with severely reduced kidney function present
with high sFLC levels as the direct cause in almost all
cases. Alternatively in mild to moderate renal impair-
ment in myeloma, sFLCs may only be a small contribut-
ing factor and more likely triggered by myeloma related
co-morbidities (dehydration, hypercalcaemia and use of
non-steroidal anti-inflammatory drugs) [12]. Unrelated
co-morbidities may also play a role: in the age popula-
tion from which myeloma arises approximately 25% of
individuals have mild to moderate renal impairment
linked to age-related morbidities, such as hypertension,
cardiovascular disease and diabetes [26–28]. The relation-
ship between sFLC levels assessed by Seralite® and differ-
ent degrees of renal impairment in myeloma requires
exploration in separate studies. Further, the sensitively of
Seralite® and the suitability of the renal reference range in
monoclonal gammopathy of renal significance (MGRS)
would need to be independently validated in these disor-
ders that do not meet the criteria for multiple myeloma.
Conclusions
Serum FLC quantitation via Seralite® could be used as an
effective screening tool for myeloma in patients presenting
with AKI stage 3. The FLC ratio sensitively and specifically
distinguishes between patients with AKI and myeloma or
AKI attributable to other causes. Seralite® is easily applic-
able to testing urgent samples in routine hospital laborator-
ies and therefore could be used to speed up the diagnosis
of myeloma in AKI patients, in whom prompt intervention
is vital to provide the best chance of renal recovery and im-
prove patient prognosis.
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